shutterstock_2075328976_jhvephoto

JHVEphoto / Shutterstock.com

7 December 2021GenericsAlex Baldwin

Galderma sues Lupin over Oracea generic

Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea (doxycycline) prior to the expiration of key patents.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

More on this story

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

More on this story

Fed Circuit hands win to Galderma in Teva suit

30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Galderma fends off Dr Reddy IPR claims

17 February 2016 Galderma Laboratories has successfully avoided three inter partes review petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York